Interprotein Corporation 

A Japanese biotech company is seeking an EU partner for AI-based drug discovery

KEY ACTIVITIES Entropy-considered in silico screening of small molecules and AI-based activity prediction
SECTOR: Biotech
KEY WORDS: Protein-protein interaction, ubiquitin-proteasome system, in silico screening, artificial intelligence, activity prediction

Company Activity Description:

  1. Interprotein established a novel in silico screening platform technology that does not depends on docking simulation/molecular dynamics (MD) but is driven by binding mechanism-based selection and applicable to challenging targets including PPIs and gave it a name of INTerprotein’s Engine for New Drug Design (INTENDD).
  2. Interprotein also developed an artificial intelligence (AI)-based drug discovery platform technology (AI-guided INTENDD).  One of the strongest points of this technology is the precise separation of activity into 8 classes based on proprietary data pre-processing and resultant unique feature values.
  3. Hit rates of INTENDD-proposed compounds constantly show the values of 10% or more for PPI targets and the best rate reached up to 47%.  When we validated accuracy of AI-guided INTENDD using Runx1 inhibitor compounds whose co-crystal structure information had not been obtained, “Good Prediction” rate reached 79%, strongly suggesting that AI-guided INTENDD is applicable to activity prediction of compounds without X-ray co-crystal structure information.

Type of Partnership Sought:

1. Research cooperation agreement
2. Technical cooperation agreement
3.  License agreement
4. Financial agreement


Additional information:


  • Procedure of AI-guided INTENDD-based identification of highly active compounds

AI-guided INTENDD enables to identify an activity-optimized compound

in minimized cycles of synthesis and evaluation of compounds

without co-crystal structure information.

Company website